Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized 52 week treatment double-blind, triple-dummy parallel-group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma

Trial Profile

A multicenter randomized 52 week treatment double-blind, triple-dummy parallel-group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol/mometasone (Primary) ; Mometasone; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms PALLADIUM
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2022 Results of post-hoc analysis assessing efficacy and safety of IND/MF versus SAL/FLU in Asian patients with inadequately controlled asthma from two (PALLADIUM and IRIDIUM) published in the Journal of Asthma
    • 24 Jan 2022 A review outlining the unique strategy used in the accelerated development of IND/GLY/MF that combined various approaches comprising data from 3 study (QUARTZ and PALLADIUM evaluated IND/MF while IRIDIUM and ARGON evaluated IND/GLY/MF) published in the Advances in Therapy
    • 22 May 2021 Results (n=698) of pooled analysis from 2 trials (PALLADIUM and IRIDIUM) assessing the population pharmacokinetic (popPK) analysis of Indacaterol/Glycopyrronium/Mometasone Furoate and estimate the effect of covariates on their pharmacokinetics in patients with asthma, published in the European Journal of Drug Metabolism and Pharmacokinetics.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top